AcuFocus Inc.
AcuFocus, Inc., the global leader in corneal inlay technology announced today they are nearing their 1,000th KAMRA inlay procedure in the United States. The KAMRA inlay received US approval on April 17, 2015, making it the first corneal inlay to achieve this landmark. Since approval, the company initiated a controlled commercial release with first surgeries taking place at Hoopes Vision in Utah on May 19, 2015.
“Achieving this milestone so quickly after launching the KAMRA inlay in the United States is a testament to the consumer demand for a true solution for presbyopia,” said Jim Mazzo, Chairman and CEO of AcuFocus, Inc. “We are thrilled with the adoption rate and how clinics are making the inlay an integral part of their business.”
The KAMRA inlay is indicated for the surgical correction of presbyopia in patients (+0.50 D to -0.75 D) to improve near vision by extending depth of focus. Presbyopia is an age-related loss of near vision that affects nearly everyone over the age of 50. With the baby boomer generation now over the age of 50, the population of patients suffering from presbyopia in the United States is estimated to be more than 114 million people.i
“We have made the inlay our procedure of choice for presbyopia-correction,” said Phillip Hoopes Jr, Hoopes Vision. “For the first time, we are now able to treat a previously underserved patient population with a lasting presbyopia solution. An added benefit to the inlay is its ability to drive awareness within our community and grow all aspects of our practice.”
Early results with the inlay are mirroring the outcomes achieved in the US IDE clinical trial. On average patients achieve J2 for uncorrected near visual acuity at 1 and 3 months post-op, a gain of 4.0 lines from their pre-operative vision. Uncorrected distance visual acuity remains unchanged at 20/20 between pre-op and 3 month post-operative exams.
“US patients and practices alike are benefiting from over a decade worth of development and innovation in inlay design, diagnostics and surgical technology,” said Nicholas Tarantino, OD, Chief Clinical and Regulatory Officer for AcuFocus, Inc. “The KAMRA inlay and surgical procedure today are truly the state-of-the-art as evidenced by the exceptional commercial results.”
AcuFocus technologies will be presented at the upcoming Ophthalmic Innovators Summit and the American Academy of Ophthalmology (AAO) happening this weekend in Las Vegas, Nevada. AcuFocus will be exhibiting at the AAO meeting in booth #728.